Triazolam Stats & Data

Triazolam was patented in 1970 and subsequently entered the pharmaceutical market in the United States in 1982 under the brand name Halcion. The drug gained widespread clinical adoption, and by 2017 it ranked as the 289th most commonly prescribed medication in the United States with over one million prescriptions annually. Following its market introduction, triazolam became the subject of regulatory scrutiny in several countries due to concerns about adverse psychological reactions, particularly at higher dose ranges. Some nations temporarily withdrew the drug from their markets, though subsequent review by the FDA and regulatory bodies in most other countries reaffirmed its safety profile when used at lower doses with appropriate clinical guidance and labeling. Beyond its primary indication for insomnia, triazolam has found particular utility in specific clinical and practical contexts. It is frequently prescribed to airline passengers as a sleep aid for short- to medium-duration flights. Additionally, the drug's pronounced amnestic properties have made it a common choice in sedation dentistry, where its ability to induce anterograde amnesia helps patients undergo dental procedures with minimal subsequent recall of the experience.

Effects aggregated from 48 experience reports (48 Erowid)

Dose distribution from experience reports

From 30 individual dose entries

Most common forms and preparations reported

Dose relative to body weight from reports with weight data

Redosing behavior across 44 reports